Nonalcoholic Fatty Liver Disease

Patients with non-alcoholic fatty liver disease who underwent endoscopic bariatric and metabolic therapies saw improvements in liver fibrosis and other outcomes, according to study results.

CPAP alone did not improve hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease and obstructive sleep apnea, researchers reported in the American Journal of Respiratory and Critical Care Medicine.

Patients with non-alcoholic fatty liver disease had a moderately increased risk for extrahepatic cancers, such as gastrointestinal, breast and gynecological cancers, according to a meta-analysis.

Exposure to passive smoking from childhood through adulthood was associated with increased risk for non-alcoholic fatty liver disease, according to study results.

The AGA Institute Clinical Practice Updates Committee and the Governing Board published evidence-based intervention advice for lifestyle modifications for treating nonalcoholic fatty liver disease in Gastroenterology.

Patients with inflammatory bowel disease who also had non-alcoholic fatty liver disease had higher readmission rates, according to research presented at Crohn’s and Colitis Congress.

Nonalcoholic steatohepatitis is the second leading indication for liver transplantation in the United States but there are currently no FDA-approved treatments available.

There is a significant medical need to find effective pharmacotherapies to manage NASH, the liver disease that is really a pandemic.

Ideal CV health behaviors were associated with lower nonalcoholic fatty liver disease, or NAFLD, prevalence among participants in the Multi-Ethnic Study of Atherosclerosis cohort.

Moderate alcohol consumption is associated with an increased risk for advanced fibrosis in nonalcoholic fatty liver disease, with the risk highest among those with type 2 diabetes, according to study data.